Israel - English - Ministry of Health

takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 4 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

takeda malaysia sdn bhd - ixazomib citrate -

European Union - English - EMA (European Medicines Agency)

takeda pharma a/s - ixazomib citrate - multiple myeloma - antineoplastic agents - ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

takeda malaysia sdn bhd - ixazomib citrate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

takeda malaysia sdn bhd - ixazomib citrate -

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - ixazomib citrate (unii: 46cwk97z3k) (ixazomib - unii:71050168a2) - ixazomib 4 mg - ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. none. women should avoid becoming pregnant while being treated with ninlaro. risk summary ninlaro can cause fetal harm when administered to a pregnant woman. there are no human data available regarding the potential effect of ninlaro on pregnancy or development of the embryo or fetus. ixazomib caused embryo-fetal toxicity in pregnant rats and rabbits at doses resulting in exposures that were slightly higher then those observed in patients receiving the recommended dose [see data]. advise women of the potential risk to a fetus and to avoid becoming pregnant while being treated with ninlaro. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. data animal data in an embryo-fetal development study in pregnant rabbits there were

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

takeda pharma as, denmark, denmark - ixazomib - tablets - 3 mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

takeda pharma as, denmark, denmark - ixazomib - tablets - 2.3 mg

Canada - English - Health Canada

takeda canada inc - ixazomib (ixazomib citrate) - capsule - 2.3mg - ixazomib (ixazomib citrate) 2.3mg - antineoplastic agents

Canada - English - Health Canada

takeda canada inc - ixazomib (ixazomib citrate) - capsule - 3mg - ixazomib (ixazomib citrate) 3mg - antineoplastic agents